financetom
DXCM
financetom
/
Healthcare
/
DXCM
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
DexCom, Inc.DXCM
81.07USD
+2.57 (3.27%)
Jan 3, 2025, 4:00 PM - At close
81.21USD
+0.14 (0.17%)
Jan 3, 2025, 7:22 PM EST - Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
31.67B
Revenue (ttm)
3.95B
Net Income (ttm)
680.80M
Shares Out
390.60M
EPS (ttm)
1.67
PE Ratio
48.62
Forward PE
41.89
Dividend
n/a
Ex-Dividend Date
n/a
Volume
2,613,940
Open
79.00
Previous Close
78.50
Day's Range
78.55 - 81.22
52-Week Range
62.34 - 142.00
Beta
1.13
Analysts
Buy
Price Target
98.00 (+20.88%)
Earnings Date
Feb 6, 2025
Description >

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.

Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.

It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Copyright 2023-2025 - www.financetom.com All Rights Reserved